Skimune® represents the fruits of over 30 years’ research on haematopoietic stem cell transplantation and Graft versus Host Disease (GvHD) by Alcyomics CEO, Anne Dickinson Emeritia Professor of Translational and Clinical Medicine at Newcastle University, who used human skin based in vitro assays for identifying responses of donor cells against patient skin tissue i.e. graft versus host disease (GvHD) following haematopoietic stem cell transplantation. Her research work that has been extensively published in over 100 peer-reviewed journals. This skin explant predictive assay for GvHD has been used in Newcastle as part of a clinical protocol for treatment of haematological disorders and has been published to have a >80% correlation with clinical outcome. Since GvHD affects more than one target organ e.g. skin, gut and liver, the assay is predictive of systemic disease.

In 2007, Anne realised the commercial potential of human skin based in vitro models for predicting adverse immune responses. She went on to create Alcyomics Ltd as a spin out of Newcastle University.?

Since the incorporation of the company, the service portfolio has significantly increased by the development of invitro models of disease e.g. atopic dermatitis, osteoarthritis and innervated models for drug discovery and efficacy testing. Our drive to extend our service offerings continues with an excellent team of experienced scientists.

A proven, experienced CRO and service-provider, Alcyomics has developed unique non-animal non-artificial human based in vitro assays that transform drug development by enabling early and accurate identification of safe and efficacious compounds.

Our sensitive and highly customisable assays significantly improve the testing process making it faster, more effective and better at predicting clinical outcomes. We help clients reduce the cost of drug development, reduce the use of animal models and improve speed to market whilst providing a better return on investment.

Skimune AD - Brochure

Contact supplier